Yi Lee, MD
@Yi_Lee_Olive
Followers
114
Following
341
Statuses
140
HemOnc Fellow @DartmouthHemOnc | IM @waynemedicine @THO_WSU_IM | Former Trainee @DanaFarber @harvardmed | Pianist 🎹
Lebanon, NH
Joined January 2022
RT @CharlesJiangMD: As an oncologist, I discovered something shocking: Medicare Part D requires prior authorization for ondansetron (Zofran…
0
23
0
RT @TheBloodMD: Dr. Anne Christine Buteau’s podium presentation of a Dartmouth Breast Cancer trial at the historic Mt. Washington Hotel. @…
0
3
0
RT @TheBloodMD: I’m so proud of our fellows and faculty @DartmouthHemOnc. Engaging H&N lecture by @WaspGarrett today. Then our first “Conne…
0
2
0
RT @OncBrothers: #LungSeries: This is the #Algorithm we have used during our discussion with @FordePatrick for early + locally advanced NSC…
0
31
0
RT @Erman_Akkus: 🟠Trials in advanced pancreatic cancer👇 ❌Failure and ✅Success @myESMO @OncoAlert #cancer #oncology #pancreatic #MedX http…
0
64
0
RT @kunhsingyu: Excited to share that our paper on a foundation AI model for cancer prognosis and pathology diagnosis is published in Natur…
0
25
0
RT @StephenVLiu: For those implementing the MARIPOSA-2 regimen of amivantamab + chemotherapy in #EGFR NSCLC post-osimertinib, highlighting…
0
41
0
Very helpful updated algorithms.
Updated (non-exhaustive) breast cancer treatment algorithms, now including adjuvant ribociclib and other recent updates. I am happy to be running out of space as treatment options continue to expand! @OncoAlert #bcsm
0
0
2
RT @ronanhsieh: zolbetuximab showed clear benefits in CLDN18.2-expressing GE cancers. I have been talking to patients for this drug for a y…
0
1
0
RT @DrChoueiri: 1/ Results from #TiNivo2 are out both @myEsmo #ESMO24 and @TheLancet! Another phase 3 trial to assess the efficacy of immun…
0
50
0
RT @OncBrothers: Day 1 #ESMO24 Highlights #CommunityOncology 1. #TiNivo2 ��2L mRCC @DrChoueiri 2. #LITESPARK005: 2L mRCC @brian_rini 3…
0
52
0
RT @MatthewHoMD: Workup of von willebrand disease ref: ASTH ISTH NHF WFH 2021 guidelines, uptodate
0
114
0
RT @chulkimMD: #FLOWERS: #osimertinib +/- #savolitinib as 1L in de novo MET aberrant (amp/overexpression), EGFR+ aNSCLC ORR: 90.5% (n=21)…
0
34
0
I’m stoked to find that Federer is coming to Dartmouth as the Commencement speaker this June. Growing up, he has been an inspiration to me. Can’t wait to see him here at the Green!
0
0
5
RT @MatthewHoMD: Lymphoma Classification Any suggestions/critiques? @AaronGoodman33 @nihardesai7 @dgermain21 @Eddie_Cliff @CharlesMilrod…
0
348
0
RT @JamshedNamirah: J-1 visa IMG deserve to visit their homeland without fear of visa issues. Issue visa for entirety of their training! #m…
0
377
0
RT @AaronGoodman33: How I do AML induction 1 tweet (it's not complicated) Fit 7+3+gemtuzumab only t(8;21) or inv(16) 7+3+midostaurin FLT3…
0
129
0
RT @IvyLorena_Md: @ASCO volunteer application submitted!! As a 3rd year fellow who will be transitioning soon into a junior faculty positi…
0
5
0
RT @DartmouthHemOnc: Seasons Greetings from Dartmouth Cancer Center Hematology/Oncology Fellows!! May your Holiday Season be merry, full of…
0
4
0